Dark

CCCC
C4 Therapeutics Inc
stock NASDAQ

At Close

11/29/2022 3:59:55 PM EST

7.99USD+0.503%(+0.04)928,120

8.00Bid 9.60Ask 1.60Spread IEX

Pre-market

11/25/2022 8:58:30 AM EST

7.92USD-0.433%(-0.03)0

After-hours

11/29/2022 4:01:30 PM EST

8.00USD+0.125%(+0.01)0

Overview Option Chain HistoricalMore

open chart

Market Cap

391.166M

Industry

Biotechnology

Next Earnings

2023-02-23 (86d)

CCCC Stats

Avg. Vol. 10 Day

408,121

Avg. Vol. 30 Day

482,695

Employees

121

Market Cap

391,166,486

Shares Out.

48,957,007

Float

36,968,415

On/Off Exchange

61%/39%

6 Month Beta

1.87

1 Year Beta

2.05

2 Year Beta

1.82

3 Year Beta

1.73

52 Week Low

4.84

52 Week High

38.05

SMA50

8.92

SMA200

9.03

1 Week

-14.82%

1 Month

-16.25%

3 Month

-25.26%

6 Month

+10.06%

1 Year

-77.78%

2 Year

-76.64%

Jan 10, 2022

07:36AM EST C4 Therapeutics Announces 2022 Targets Benzinga

07:00AM EST Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022 GlobeNewswire Inc

Jan 3, 2022

07:00AM EST C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST. GlobeNewswire Inc

Dec 17, 2021

08:12AM EST C4 Therapeutics Reports Will Be Added To NASDAQ Biotech Index, Effective Dec. 20, 2021 Benzinga

08:00AM EST C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021. GlobeNewswire Inc

More News

Profile

C4 Therapeutics is a biopharmaceutical company focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.

CCCC Stock Summary

C4 Therapeutics Inc (NASDAQ:CCCC) stock price today is $7.99, and today's volume is 928,120. CCCC is up 0.503% today. The 30 day average volume is 482,695. CCCC market cap is 391.166M with 48,957,007 shares outstanding.

.dark-mode .JFStBX{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .JFStBX{ color: #333333; background-color: white; border: 2px solid #333333; }CCCCC4 Therapeutics Incstock NASDAQ

CCCC Stock Summary

CCCC
C4 Therapeutics Inc
stock NASDAQ